Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity
Luis G. Guijarro,
David Cano-Martínez,
M. Val Toledo-Lobo,
Lidia Ruiz-Llorente,
María Chaparro,
Iván Guerra,
Marisa Iborra,
José Luis Cabriada,
Luis Bujanda,
Carlos Taxonera,
Valle García-Sánchez,
Ignacio Marín-Jiménez,
Manuel Barreiro-de Acosta,
Isabel Vera,
María Dolores Martín-Arranz,
Francisco Mesonero,
Laura Sempere,
Fernando Gomollón,
Joaquín Hinojosa,
Sofía Zoullas,
Jorge Monserrat,
Cesar Menor-Salvan,
Melchor Alvarez-Mon,
Javier P. Gisbert,
Miguel A. Ortega,
Borja Hernández-Breijo
Affiliations
Luis G. Guijarro
Department of System Biology, University of Alcalá, 28805 Alcalá de Henares, Madrid, Spain
David Cano-Martínez
Department of System Biology, University of Alcalá, 28805 Alcalá de Henares, Madrid, Spain
M. Val Toledo-Lobo
Department of Biomedicine and Biotechnology, University of Alcalá, 28805 Alcalá de Henares, Madrid, Spain
Lidia Ruiz-Llorente
Department of System Biology, University of Alcalá, 28805 Alcalá de Henares, Madrid, Spain
María Chaparro
Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid, 28049 Madrid, Madrid, Spain
Iván Guerra
Gastroenterology Unit, Hospital Universitario de Fuenlabrada, Instituto de Investigación Hospital Universitario La Paz (IdiPaz), 28029 Fuenlabrada, Madrid, Spain
Marisa Iborra
Gastroenterology Unit, Hospital Universitario de La Fe (CIBEREHD), 46026 Valencia, Valencia, Spain
José Luis Cabriada
Gastroenterology Unit, Hospital Universitario de Galdakano, 48960 Galdakao, Vizcaya, Spain
Luis Bujanda
Gastroenterology Unit, Hospital Universitario de Donostia, 20014 San Sebastián, Guipúzcoa, Spain
Carlos Taxonera
Gastroenterology Unit, Hospital Universitario Clínico San Carlos, IdISSC, 28040 Madrid, Madrid, Spain
Valle García-Sánchez
Gastroenterology Unit, Hospital Universitario Reina Sofía, 14004 Córdoba, Córdoba, Spain
Background: Recently, increased tissue levels of AIF-1 have been shown in experimental colitis, supporting its role in intestinal inflammation. Therefore, we studied the levels of AIF-1 in Crohn’s disease (CD). Methods: This study included 33 patients with CD (14 men and 19 women) who participated in the PREDICROHN project, a prospective multicenter study of the Spanish Group of Inflammatory bowel disease (GETECCU). Results: This article demonstrates declines with respect to baseline levels of serum AIF-1 in Crohn’s disease (CD) patients after 14 weeks of treatment with anti-TNFs. Furthermore, in patients with active CD (HB ≥ 5), serum AIF-1 levels were significantly higher than those in patients without activity (HB ≤ 4). The study of serum AIF-1 in the same cohort, revealed an area under the ROC curve (AUC) value of AUC = 0.66 (p = 0.014), while for the CRP (C-reactive protein), (AUC) value of 0.69 (p = 0.0066), indicating a similar ability to classify CD patients by their severity. However, the combination of data on serum levels of AIF-1 and CRP improves the predictive ability of these analyses for classifying CD patients as active (HB ≥ 5) or inactive (HB ≤ 4). When we used the odds ratio (OR) formula, we observed that patients with CRP > 5 mg/L or AIF-1 > 200 pg/mL or both conditions were 13 times more likely to show HB ≥ 5 (active CD) than were those with both markers below these thresholds. Conclusion: The development of an algorithm that includes serum levels of AIF-1 and CRP could be useful for assessing Crohn’s disease severity.
